Rabrazo-DSR (Capsules)

Description

Understanding Rabrazo-DSR
 Rabrazo-DSR, developed by Sanchem, is presumed to be a combination of Rabeprazole and sustained-release Domperidone, used to manage acid-related gastrointestinal conditions with associated motility symptoms.

How It Works
 Rabeprazole irreversibly inhibits the H+/K+-ATPase proton pump in gastric parietal cells, reducing acid secretion. Domperidone is a dopamine antagonist that enhances gastric and upper GI motility and has antiemetic properties, helping relieve nausea, bloating, and early satiety that often accompany acid-reflux conditions.

Common Areas of Use
 GERD, acid-related dyspepsia, gastritis-related discomfort, and associated nausea or bloating, as diagnosed by a physician.

Dosage and Administration
 Typically taken once daily before a meal, as directed. Capsules should be swallowed whole and not crushed or opened unless a physician specifically advises otherwise.

Safety Information
 Domperidone carries cardiac considerations (QT-interval prolongation risk), so caution is needed in patients with cardiac conditions or those on interacting medications. Caution is also advised in patients with significant hepatic impairment or hormone-sensitive conditions. Patients should disclose all current medications, cardiac history, and pregnancy or breastfeeding status.

Quality You Can Trust
 Every batch of Rabrazo-DSR is manufactured in a GMP-compliant facility, with rigorous testing to ensure consistent potency, purity, and dissolution performance appropriate to its sustained-release design.

Why Choose Sanchem's Rabrazo-DSR
 Rabrazo-DSR reflects Sanchem's commitment to providing effective, well-manufactured therapies for acid-related gastrointestinal conditions.

A Note for Healthcare Professionals
 Sanchem welcomes healthcare providers to reach out for full prescribing information and cardiac safety data relevant to Rabrazo-DSR.